HC Wainwright Reiterates Buy Rating for Karyopharm Therapeutics (NASDAQ:KPTI)

HC Wainwright reiterated their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTIFree Report) in a research report report published on Monday morning, Benzinga reports. They currently have a $8.00 target price on the stock.

Karyopharm Therapeutics Stock Up 7.3 %

Karyopharm Therapeutics stock opened at $0.99 on Monday. Karyopharm Therapeutics has a 12-month low of $0.62 and a 12-month high of $2.47. The business’s 50-day moving average price is $1.17 and its two-hundred day moving average price is $1.08. The stock has a market cap of $123.92 million, a PE ratio of -0.78 and a beta of 0.25.

Karyopharm Therapeutics (NASDAQ:KPTIGet Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.01. The firm had revenue of $33.13 million for the quarter, compared to analyst estimates of $35.02 million. As a group, analysts expect that Karyopharm Therapeutics will post -1.25 earnings per share for the current year.

Insider Activity

In other news, Director Deepika Pakianathan sold 360,744 shares of Karyopharm Therapeutics stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $1.00, for a total transaction of $360,744.00. Following the sale, the director now directly owns 11,209 shares of the company’s stock, valued at $11,209. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 579,066 shares of company stock valued at $571,499. 4.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in KPTI. Barclays PLC lifted its stake in shares of Karyopharm Therapeutics by 4.2% in the third quarter. Barclays PLC now owns 1,152,298 shares of the company’s stock worth $1,544,000 after acquiring an additional 45,937 shares during the period. Wade G W & Inc. acquired a new position in shares of Karyopharm Therapeutics in the third quarter worth approximately $60,000. Silverarc Capital Management LLC lifted its stake in shares of Karyopharm Therapeutics by 8.3% in the third quarter. Silverarc Capital Management LLC now owns 561,955 shares of the company’s stock worth $753,000 after acquiring an additional 42,970 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Karyopharm Therapeutics in the third quarter worth approximately $762,000. Finally, Exchange Traded Concepts LLC lifted its stake in shares of Karyopharm Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 115,864 shares of the company’s stock worth $100,000 after acquiring an additional 29,380 shares during the period. 66.44% of the stock is owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

(Get Free Report)

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

Further Reading

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.